Why the study?
Decreased thrombomodulin expression in bladder cancer tissue is linked to malignancy, prompting evaluation of its immunoexpression across histological subtypes and association with patient survival.
Does thrombomodulin immunoexpression score predict survival in patients with bladder cancer?
Does thrombomodulin immunoexpression score predict survival in patients with bladder cancer?
Low thrombomodulin immunoexpression in bladder cancer tissue is associated with poorer patient survival and may serve as a prognostic biomarker.
No takes yet. Share an insight, caveat, or question.
TM immunoexpression may aid prognostic stratification in bladder cancer; leaves open validation beyond standard clinicopathologic factors.
Watt et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: